Skip to content 
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. more
| Time Frame | CSCI | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -10.12% | -2.12% | 0.77% |
| 1-Month Return | -20.75% | -2.54% | 2.65% |
| 3-Month Return | -29.66% | -6.28% | 12.3% |
| 6-Month Return | -61.67% | -1.36% | 13.48% |
| 1-Year Return | -68.6% | 9.29% | 33.47% |
| 3-Year Return | -93.61% | 10.05% | 32.22% |
| 5-Year Return | -96.73% | 43.69% | 92.85% |
| 10-Year Return | -99.96% | 103.1% | 194.31% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
|---|---|---|---|---|---|---|
| Total Revenue | 11.86M | 13.49M | 13.88M | 7.26M | [{"date":"2020-12-31","value":85.43,"profit":true},{"date":"2021-12-31","value":97.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.31,"profit":true}] | |
| Cost of Revenue | 5.88M | 5.28M | 5.76M | 4.28M | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.72,"profit":true},{"date":"2022-12-31","value":98,"profit":true},{"date":"2023-12-31","value":72.77,"profit":true}] | |
| Gross Profit | 5.98M | 8.21M | 8.12M | 2.98M | [{"date":"2020-12-31","value":72.81,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.88,"profit":true},{"date":"2023-12-31","value":36.33,"profit":true}] | |
| Gross Margin | 50.41% | 60.87% | 58.48% | 41.07% | [{"date":"2020-12-31","value":82.81,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.07,"profit":true},{"date":"2023-12-31","value":67.46,"profit":true}] | |
| Operating Expenses | 10.02M | 10.90M | 9.83M | 11.98M | [{"date":"2020-12-31","value":83.64,"profit":true},{"date":"2021-12-31","value":90.97,"profit":true},{"date":"2022-12-31","value":82.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
| Operating Income | 1.84M | 2.59M | 4.05M | (4.72M) | [{"date":"2020-12-31","value":45.42,"profit":true},{"date":"2021-12-31","value":63.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-116.38,"profit":false}] | |
| Total Non-Operating Income/Expense | (384.66K) | (3.62K) | 204.79K | 264.38K | [{"date":"2020-12-31","value":-145.5,"profit":false},{"date":"2021-12-31","value":-1.37,"profit":false},{"date":"2022-12-31","value":77.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
| Pre-Tax Income | 1.46M | 2.59M | 4.26M | (4.45M) | [{"date":"2020-12-31","value":34.2,"profit":true},{"date":"2021-12-31","value":60.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-104.57,"profit":false}] | |
| Income Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
| Income From Continuous Operations | 1.46M | 2.64M | 3.24M | (3.55M) | [{"date":"2020-12-31","value":44.92,"profit":true},{"date":"2021-12-31","value":81.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-109.56,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
| Net Income | 1.46M | 2.64M | 3.24M | (3.55M) | [{"date":"2020-12-31","value":44.92,"profit":true},{"date":"2021-12-31","value":81.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-109.56,"profit":false}] | |
| EPS (Diluted) | (45.86) | (6.98) | (18.72) | (13.64) | [{"date":"2020-12-31","value":-4585.75,"profit":false},{"date":"2021-12-31","value":-698.01,"profit":false},{"date":"2022-12-31","value":-1872.12,"profit":false},{"date":"2023-12-31","value":-1364,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| CSCI | |
|---|---|
| Current Ratio | 3.46 |
| Quick Ratio | 3.05 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CSCI | |
|---|---|
| ROA (LTM) | -23.34% |
| ROE (LTM) | -65.92% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CSCI | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.54 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CSCI | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 2.66 |
| P/B | 0.49 |
| Price/FCF | NM |
| EV/R | 2.67 |
| EV/Ebitda | 3.33 |
COSCIENS Biopharma Inc. (CSCI) share price today is $2.8134
Yes, Indians can buy shares of COSCIENS Biopharma Inc. (CSCI) on Vested. To buy COSCIENS Biopharma Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CSCI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of COSCIENS Biopharma Inc. (CSCI) via the Vested app. You can start investing in COSCIENS Biopharma Inc. (CSCI) with a minimum investment of $1.
You can invest in shares of COSCIENS Biopharma Inc. (CSCI) via Vested in three simple steps:
The 52-week high price of COSCIENS Biopharma Inc. (CSCI) is $11.1. The 52-week low price of COSCIENS Biopharma Inc. (CSCI) is $2.62.
The price-to-earnings (P/E) ratio of COSCIENS Biopharma Inc. (CSCI) is
The price-to-book (P/B) ratio of COSCIENS Biopharma Inc. (CSCI) is 0.49
The dividend yield of COSCIENS Biopharma Inc. (CSCI) is 0.00%
The market capitalization of COSCIENS Biopharma Inc. (CSCI) is $13.08M
The stock symbol (or ticker) of COSCIENS Biopharma Inc. is CSCI
Link copied 
